What's going on with gonorrhoea?
Gonorrhoea is one of the most common sexually transmitted infections (STIs) in the world, and the second most common in Europe. Much has been written in the press lately about its spread across the European continent and there are concerns that the STI is becoming untreatable and resistant to antibiotics. On the 6 June 2012, the World Health Organisation (WHO) declared that there is “urgent action needed to prevent the spread of untreatable gonorrhoea.”
That was after new figures revealed that cases of gonorrhoea have increased dramatically in Europe over the past few years. According to figures from the European Centre for Disease Prevention and Control’s (ECDC) recent surveillance programme on the infection, during 2010 there were more than 32,000 incidences of gonorrhoea.
But what has happened for it to get this far? The simple answer is: because people are having unsafe safe. The ECDC data from 2010 showed that gonorrhoea was reported three times more often in men than in women and the STI was most commonly found in young adults; 45 percent of all cases occur in the 15 to 24 age bracket.
This view was echoed by the Health Protection Agency (HPA) in May, when it was announced that in England alone cases of gonorrhoea increased by a quarter in 2011. Speaking at the time, Dr Gwenda Hughes, the head of STI surveillance at the HPA, said: “The 2011 data is a matter of concern regarding young heterosexuals and men who have sex with men. We anticipated some increase in diagnoses due to improvements in testing in recent years, but not on the scale seen here. This data shows that too many people are putting themselves at risk of STIs and serious health problems by having unsafe sex.”
So cases of gonorrhoea are increasing, but that is not the most concerning part. Within the 32,000 cases of gonorrhoea that were identified two year ago, nine percent were resistant to the antibiotics used to treat them, increasing from four percent the year before. The ECDC figures also revealed that antibiotic resistant cases were indentified in 17 European countries, whereas in 2009 this figure only stood at seven.
Commenting on the figures when they were released, Dr Marc Sprenger, the Director of the European Centre for Disease Prevention and Control, said: “This indicates the risk that gonorrhoea may become an untreatable disease in the near future.”
There are a number of antibiotics that gonorrhoea is now resistant to, including sulphonamides, penicillin, tetracyclines and quinolones. Current treatment advice in Europe stipulates the use of third-generation cephalosporins; ceftriaxone or cefixime. However, there have been a number of reports that certain strains of gonorrhoea are now becoming resistant to treatment methods.
“Millions of people with gonorrhoea may be at risk of running out of treatment options unless urgent action is taken,” the WHO said last month. “Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics – the last treatment option against gonorrhoea.”
Dr Manjula Lusti-Narasimhan, from the Department of Reproductive Health and Research at WHO, affirmed: “Gonorrhoea is becoming a major public health challenge, due to the high incidence of infections accompanied by dwindling treatment options. The available data only shows the tip of the iceberg. Without adequate surveillance we won’t know the extent of resistance and without research into new antimicrobial agents, there could soon be no effective treatment for patients.”
As a result, the World Health Organisation and the ECDC issued guidelines on how to tackle this ever-increasing threat in June. Both agree a gonorrhoea surveillance plan needs to be established, to assess how far and how quickly drug resistant strains of the infection are spreading.
The ECDC goes on to say that “close collaboration between clinicians, laboratories and local public health authorities is essential in order to ensure that cases with probable or confirmed treatment failure are appropriately investigated and treated.” It also believes that increasing awareness of the threat of antibiotic resistant gonorrhoea is vital, not only among the general public, but also in politicians, policy makers and healthcare providers.
Meanwhile, the WHO says that “greater vigilance on the correct use of antibiotics and more research into alternative treatment regimens for gonococcal infections” is the best way to manage the problem. It adds: “WHO’s Global Action Plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoea also calls for increased monitoring and reporting of resistant strains as well as better prevention, diagnosis and control of gonococcal infections.”
Additionally, the HPA has its own ideas of what needs to be done, as Dr Hughes explains: “The rises in 2011 demonstrate it is crucial the work to reduce STIs continues. Improving awareness and encouraging safer sexual behaviour through health promotion and education is essential to helping prevent STIs. Coupled with this, ensuring easy access to sexual health services and STI screening is important for controlling the transmission of all STIs and needs to be focused on groups at highest risk.
“The importance of STI prevention and good sexual health becomes even clearer given emerging resistance to gonorrhoea treatment. Laboratory testing over the last five years has shown a large increase in the amount of resistance to the main drugs used to treat gonorrhoea, presenting the very real danger of untreatable gonorrhoea in the future.”
Schneider Electric's intelligent patient room: need to know
Schneider Electric has launched a virtual showcase that features its new "intelligent patient room". What is it exactly?
Who: Schneider Electric is a multinational that develops energy and automation solutions for many different industries - including hospitality, education, defence, and healthcare. Founded in 1836, today it is a Fortune 500 company, and it currently provides technology to 40% of hospitals around the world, among them Penn Medicine, one of the top hospitals in the US where Schneider's EcoStruxure for Healthcare is deployed, an IoT solution.
What: Schneider has launched its Innovation Experience Live Healthcare Lab, an immersive experience that takes visitors through a demonstration of a hospital, including the doctor’s office, the operating room, and the intelligent patient room.
The room features a digital patient footwall - a touchscreen that creates a single reference point for patients, families and healthcare providers, by incorporating care information, entertainment and environmental controls all in one place. A separate digital patient door display has important information for healthcare staff.
All Schneider's equipment is low-voltage, and integrated so that the patient room, clinical needs and IT are all seamlessly connected, what Schneider calls a digital “system of systems.”
Why: Mike Sanders, Customer Projects & Services in Healthcare Innovation at Schneider Electric, explains: “The hospital of the future will need to put the patient experience at the forefront, using innovative and connected systems to provide superior in-hospital care experiences.”
“With the shift to remote work and business brought forth by the pandemic, we knew that we needed to invest in a new virtual experience that showcases our vision for a truly integrated healthcare experience. We believe our intelligent patient room is the solution that our healthcare partners and customers have been looking for, and we’re excited to offer a way for them to experience it no matter where they are in the world.”
Where: The virtual experience was modelled after the new innovations installed at Penn Medicine in Philadelphia, the first real-world installation of Schneider Electric’s fully integrated intelligent patient room technology. It is currently being hosted at the company’s St. Louis Innovation Hub and Innovation Executive Briefing Center (IEBC) facility.